Literature DB >> 16368994

Complement and Fc function are required for optimal antibody prophylaxis against Pneumocystis carinii pneumonia.

Jesse Wells1, Constantine G Haidaris, Terry W Wright, Francis Gigliotti.   

Abstract

Pneumocystis carinii is an opportunistic fungal pathogen that causes P. carinii pneumonia (PCP) in the immunocompromised host. We investigated the role of antibody Fc-mediated function in passive prophylaxis against the development of PCP in SCID mice. By comparison of anti-mouse P. carinii immunoglobulin G1 monoclonal antibody (MAb) 4F11(G1) and its F(ab')2 derivative in an intranasal immunoprophylaxis model, we determined that Fc-mediated function is required for maximum effect of this antibody. Comparison of efficacy of antibody prophylaxis in SCID mice depleted of complement to that in nondepleted mice demonstrated that complement fixation by MAb 4F11(G1) is also necessary for optimal effect of passively administered antibody, although residual protection was observed in complement-depleted SCID mice. The necessity of complement for optimal PCP prophylaxis by MAb 4F11(G1) suggests that complement may play a role in antibody-mediated protection against development of PCP.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16368994      PMCID: PMC1346672          DOI: 10.1128/IAI.74.1.390-393.2006

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  Cutting Edge: NK cells mediate IgG1-dependent hyperacute rejection of xenografts.

Authors:  Dengping Yin; Huasong Zeng; Lianli Ma; Jikun Shen; Hui Xu; Guerard W Byrne; Anita S Chong
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

2.  Conditions which favor the C1-fixation by mouse IgG1.

Authors:  M Okada; K Takahashi; S Utsumi
Journal:  Mol Immunol       Date:  1983-03       Impact factor: 4.407

3.  Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3.

Authors:  Scott Shapiro; David O Beenhouwer; Marta Feldmesser; Carlos Taborda; Michael C Carroll; Arturo Casadevall; Matthew D Scharff
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

4.  Passive intranasal monoclonal antibody prophylaxis against murine Pneumocystis carinii pneumonia.

Authors:  Francis Gigliotti; Constantine G Haidaris; Terry W Wright; Allen G Harmsen
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

5.  NK cells use perforin rather than granulysin for anticryptococcal activity.

Authors:  Ling Ling Ma; Christopher L C Wang; Graham G Neely; Slava Epelman; Alan M Krensky; Christopher H Mody
Journal:  J Immunol       Date:  2004-09-01       Impact factor: 5.422

6.  Epitope mapping of a protective monoclonal antibody against Pneumocystis carinii with shared reactivity to Streptococcus pneumoniae surface antigen PspA.

Authors:  Jesse Wells; Francis Gigliotti; Patricia J Simpson-Haidaris; Constantine G Haidaris
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.

Authors:  H Masur; M A Michelis; J B Greene; I Onorato; R A Stouwe; R S Holzman; G Wormser; L Brettman; M Lange; H W Murray; S Cunningham-Rundles
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

8.  Clearance of Pneumocystis carinii in mice is dependent on B cells but not on P carinii-specific antibody.

Authors:  Frances E Lund; Kevin Schuer; Melissa Hollifield; Troy D Randall; Beth A Garvy
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

9.  Characterization of transmission of Pneumocystis carinii f. sp. muris through immunocompetent BALB/c mice.

Authors:  F Gigliotti; A G Harmsen; T W Wright
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

Review 10.  Current epidemiology of Pneumocystis pneumonia.

Authors:  Alison Morris; Jens D Lundgren; Henry Masur; Peter D Walzer; Debra L Hanson; Toni Frederick; Laurence Huang; Charles B Beard; Jonathan E Kaplan
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

View more
  16 in total

1.  A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.

Authors:  Kristen N Delaney; James P Phipps; John B Johnson; Steven B Mizel
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

2.  Novel pneumocystis antigen discovery using fungal surface proteomics.

Authors:  Mingquan Zheng; Yang Cai; Taylor Eddens; David M Ricks; Jay K Kolls
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

3.  Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia.

Authors:  Derrick R Samuelson; Nicholas M de la Rua; Tysheena P Charles; Sanbao Ruan; Christopher M Taylor; Eugene E Blanchard; Meng Luo; Alistair J Ramsay; Judd E Shellito; David A Welsh
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

Review 4.  Antibody-mediated protection through cross-reactivity introduces a fungal heresy into immunological dogma.

Authors:  Arturo Casadevall; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-08-20       Impact factor: 3.441

Review 5.  Current understanding of Pneumocystis immunology.

Authors:  Michelle N Kelly; Judd E Shellito
Journal:  Future Microbiol       Date:  2010-01       Impact factor: 3.165

6.  An Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia.

Authors:  Jay K Kolls
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914

Review 7.  The protective role of immunoglobulins in fungal infections and inflammation.

Authors:  Sri Ramulu Elluru; Srini V Kaveri; Jagadeesh Bayry
Journal:  Semin Immunopathol       Date:  2014-11-18       Impact factor: 9.623

Review 8.  Complement system in lung disease.

Authors:  Pankita H Pandya; David S Wilkes
Journal:  Am J Respir Cell Mol Biol       Date:  2014-10       Impact factor: 6.914

Review 9.  Pathological and protective immunity to Pneumocystis infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Semin Immunopathol       Date:  2014-11-25       Impact factor: 9.623

10.  Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions.

Authors:  Gregory L Moore; Hsing Chen; Sher Karki; Greg A Lazar
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.